STOCK TITAN

Molecular Templates, Inc. - MTEM STOCK NEWS

Welcome to our dedicated page for Molecular Templates news (Ticker: MTEM), a resource for investors and traders seeking the latest updates and insights on Molecular Templates stock.

Molecular Templates, Inc. (Nasdaq: MTEM) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of targeted therapeutics for oncology. The company leverages its innovative proprietary platform, engineered toxin bodies (ETBs), which are designed to selectively target and kill tumor cells, offering a novel approach to cancer treatment.

MTEM's leading immunotoxin, MT-3724, is in clinical development for non-Hodgkin's lymphoma. In addition to MT-3724, the company's robust pipeline includes MT-6402, targeting PD-L1, and MT-8421, targeting CTLA-4, both aimed at different forms of cancer. MT-0169, another advanced candidate, targets CD38 and is being developed for potential use in various oncology indications.

Recently, MTEM announced significant progress in its clinical trials. The first patient has been dosed in a Phase 1 clinical trial of MT-8421 for the treatment of advanced solid tumors. This study is a multi-center, open-label, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-8421. The trial will enroll patients with tumors where CTLA-4 inhibitors have shown benefits, including melanoma, hepatocellular carcinoma, non-small cell lung cancer, and others.

MT-6402, another promising candidate, has shown encouraging results in Phase 1 studies, particularly in heavily pre-treated head and neck cancer patients. The drug demonstrated objective responses and evidence of tumor regression in patients who had progressed on multiple lines of treatment.

Financially, MTEM reported third-quarter 2023 revenues of $6.8 million, reflecting a notable increase from the previous year, driven primarily by collaborative research and development agreements. However, the company continues to operate at a net loss, with efforts focused on reducing operational costs and extending its cash runway into the second quarter of 2024.

Rhea-AI Summary

Molecular Templates (MTEM) reported fourth quarter 2020 financial results, highlighting significant advancements in its clinical pipeline, including collaborations and funding. The company has four clinical-stage programs, with MT-5111 targeting HER2 and TAK-169 targeting CD38 in partnership with Takeda. MTEM secured a $70 million upfront payment from Bristol Myers Squibb for a strategic collaboration and raised $75.9 million through an equity offering. However, the net loss increased to $28.4 million from $15.9 million year-over-year, with revenues declining to $3.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.81%
Tags
-
Rhea-AI Summary

Molecular Templates (Nasdaq: MTEM) announced its participation in three major healthcare conferences: the Cowen 41st Annual Health Care Conference, Barclays Global Healthcare Conference, and Oppenheimer 31st Annual Healthcare Conference. The Cowen conference is scheduled for March 1-4, with a presentation on March 4 at 11:10 AM ET. The Barclays conference runs from March 9-11, featuring a presentation on March 10 at 3:00 PM ET. The Oppenheimer conference takes place March 16-17, with a presentation on March 17 at 11:20 AM ET. Webcasts will be accessible via MTEM's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
conferences
-
Rhea-AI Summary

Molecular Templates (Nasdaq: MTEM) announced a public offering of 6,000,000 shares at $12.65 per share, aiming to raise approximately $75.9 million in gross proceeds. The offering is expected to close around February 22, 2021, subject to customary conditions. The proceeds will fund Phase II clinical studies for MT-3724, ongoing studies for MT-5111, and development expenses in collaboration with Takeda, among other expenses. The underwriters have a 30-day option to purchase up to 900,000 additional shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
none
Rhea-AI Summary

Molecular Templates (MTEM) has initiated an underwritten public offering of its common stock, with the potential for underwriters to purchase an additional 15% of shares. The funds raised will support Phase II and Phase I clinical studies for its targeted cancer therapies, including MT-3724 and MT-5111, and development costs associated with collaborations, particularly with Takeda. The offering is contingent upon market conditions, and full details will be filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
-
Rhea-AI Summary

Molecular Templates (Nasdaq: MTEM) has secured a $70 million upfront payment from Bristol Myers Squibb as part of a strategic research collaboration aimed at discovering and developing novel therapies for oncology targets. The collaboration will leverage MTEM's engineered toxin body (ETB) platform, which focuses on targeted cancer treatments. MTEM may also receive up to $1.3 billion in additional milestone payments, alongside tiered royalties on future sales, enhancing its financial outlook significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.74%
Tags
none
-
Rhea-AI Summary

Molecular Templates (Nasdaq: MTEM) announced that the FDA accepted its IND application for MT-6402, a next-generation engineered toxin body aimed at PD-L1-positive cancers. The company plans to initiate a Phase 1 study in relapsed/refractory patients with PD-L1-positive solid tumors in 2Q21. MT-6402 employs dual mechanisms to induce an immune response against tumors. The study will include dose escalation and expansion cohorts to evaluate the efficacy of MT-6402 as a monotherapy. Updates on the trial are expected by the end of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.7%
Tags
none
Rhea-AI Summary

Molecular Templates (MTEM) announced progress in the Phase 1 study of MT5111, a HER2-targeted engineered toxin body (ETB), with 16 subjects treated and successful completion of five dosing cohorts. Pharmacokinetic data suggests that doses ≥5.0 μg/kg may be necessary for efficacy. No dose-limiting toxicities have been reported, and the most common adverse events were mild. The company plans to initiate a HER2 positive breast cancer expansion cohort in 1H21 at a dose of 10 μg/kg. The safety profile encourages further exploration of MT5111’s potential in overcoming resistance in HER2-positive cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.89%
Tags
-
Rhea-AI Summary

Molecular Templates (Nasdaq: MTEM) announced its participation in several upcoming healthcare conferences, including the Stifel 2020 Virtual Healthcare Conference and the Evercore ISI HealthCONx Conference. The Stifel conference will take place from November 16-18, with a presentation on November 17 at 9:20 am ET. The Evercore conference is scheduled for December 1-3, featuring a presentation on December 3 at 10:05 am ET. Live webcasts and presentations will be accessible through the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
-
Rhea-AI Summary

Molecular Templates (Nasdaq: MTEM) reported its Q3 2020 financial results, highlighting a net loss of $23.2 million or $0.47 per share, improved from a loss of $38.2 million in Q3 2019. Revenues increased to $4.3 million, up from $3.6 million, driven by collaborative agreements. However, the FDA placed MT-3724 clinical studies on partial clinical hold after a treatment-related fatality due to capillary leak syndrome. Current patients can continue dosing, but no new enrollments will take place until the hold is lifted. Cash reserves of $118.2 million are projected to sustain operations into H2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.18%
Tags
Rhea-AI Summary

Molecular Templates reported Q2 2020 financial results, showing a net loss of $31.2 million, or $0.68 per share, compared to a loss of $9.2 million in Q2 2019. Revenue increased to $6.9 million from $5.4 million year-over-year. The company secured a $45 million debt facility and raised $50 million via an ATM. Molecular Templates is advancing multiple ETB programs, with interim data expected in H2 2020 for MT-3724 and MT-5111. Challenges from COVID-19 have slowed patient enrollment in trials, but manufacturing operations remain uninterrupted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags

FAQ

What is the current stock price of Molecular Templates (MTEM)?

The current stock price of Molecular Templates (MTEM) is $0.14 as of December 23, 2024.

What is the market cap of Molecular Templates (MTEM)?

The market cap of Molecular Templates (MTEM) is approximately 935.6K.

What does Molecular Templates, Inc. specialize in?

Molecular Templates, Inc. specializes in the discovery and development of targeted biologic therapeutics for cancer treatment, leveraging its proprietary engineered toxin body (ETB) platform.

What is MT-3724?

MT-3724 is MTEM’s leading immunotoxin currently in clinical development for the treatment of non-Hodgkin’s lymphoma.

What recent achievements has MTEM announced?

Recently, MTEM announced the first patient dosing in a Phase 1 clinical trial for MT-8421, targeting CTLA-4, for advanced solid tumors.

What is the status of MT-6402?

MT-6402 has shown promising results in Phase 1 trials, particularly in heavily pre-treated head and neck cancer patients, demonstrating objective responses and tumor regression.

How is MTEM performing financially?

For the third quarter of 2023, MTEM reported revenues of $6.8 million, primarily from collaborative research and development agreements, though it continues to operate at a net loss.

What is the ETB platform?

The ETB platform is MTEM’s proprietary technology that uses engineered toxin bodies to selectively target and kill tumor cells, offering a novel approach to cancer treatment.

What types of cancer is MTEM targeting with its therapies?

MTEM is targeting a variety of cancers including non-Hodgkin’s lymphoma, advanced solid tumors, head and neck cancer, melanoma, hepatocellular carcinoma, non-small cell lung cancer, and more.

Who are some of MTEM's key executives?

Eric Poma, PhD, serves as the Chief Executive and Chief Scientific Officer of Molecular Templates, Inc.

What collaborations does MTEM have?

MTEM has collaborative research and development agreements, notably with Bristol Myers Squibb, among others.

Where can I find more information about MTEM?

For more detailed information, you can visit MTEM’s website at www.mtem.com.

Molecular Templates, Inc.

Nasdaq:MTEM

MTEM Rankings

MTEM Stock Data

935.57k
6.32M
3.96%
35.01%
37.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
AUSTIN